{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T21:50:13Z","timestamp":1649109013802},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"15-16","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johannes Kepler University Linz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Several clinical trials in chronic phase (CP) chronic myeloid leukemia (CML) showed that early response to tyrosine kinase inhibitor (TKI) treatment results in an improved long-term survival and progression-free survival. This study assessed whether patients achieving early treatment response (ETR; partial cytogenetic response or BCR-ABL1 mRNA \u226410% at 3\u00a0months) in daily practice also have a\u00a0long-term survival benefit.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The <jats:italic>R<\/jats:italic>etrospective <jats:italic>E<\/jats:italic>valuation o<jats:italic>f E<\/jats:italic>arly response in <jats:italic>C<\/jats:italic>ML for long-term <jats:italic>T<\/jats:italic>reatment outcome (R-EFECT), a\u00a0multicenter, retrospective chart review, documented patients with newly diagnosed CML-CP starting first-line TKI therapy in routine clinical practice. The primary aim was to assess the 5\u2011year overall survival rate.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of the 211 patients from 12\u00a0centers across Austria (January 2004\u2013May 2010), 176 (median age, 56\u00a0years) were included in the analysis. All patients received first-line therapy with imatinib. Overall, 136 patients (77.3%) achieved ETR (ETR+ group), whereas 40 (22.7%) did not reach ETR (ETR\u2212 group). The ETR+ group had higher 5\u2011year overall survival (92.5% vs. 77.5%, <jats:italic>P<\/jats:italic>\u202f=\u20090.018) and progression-free survival (95.6% vs. 87.5%, <jats:italic>P<\/jats:italic>\u202f=\u20090.06) rates compared with the ETR\u2212 group. As expected, more patients in the ETR\u2212 group were switched to another TKI. At the last contact, 120 patients were still on imatinib and 44 had switched to another TKI (25 to nilotinib, 15 to dasatinib, and 4 to bosutinib).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The data are in line with randomized trials demonstrating that ETR is associated with improved survival and thus confirmed these results in patients treated in daily clinical routine.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00508-020-01690-1","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T13:02:36Z","timestamp":1591966956000},"page":"415-422","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A\u00a0multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a\u00a0real-life setting"],"prefix":"10.1007","volume":"132","author":[{"given":"Andreas L.","family":"Petzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Buxhofer-Ausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamer","family":"Sliwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"W\u00f6lfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Dormann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Burgstaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Tinchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alois","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Goebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanow","family":"Uthman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Muenchmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"issue":"6","key":"1690_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani\u00a0M, Deininger\u00a0MW, Rosti\u00a0G, et\u00a0al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"20","key":"1690_CR2","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes\u00a0JE, Saglio\u00a0G, Kantarjian\u00a0HM, et al. Final 5\u2011year study results of DASISION: the dasatinib versus Imatinib study in treatment-naive chronic myeloid leukemia patients trial. J\u00a0Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1690_CR3","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein\u00a0B, Muller\u00a0MC, Hehlmann\u00a0R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096\u2013102.","journal-title":"Leukemia"},{"issue":"5","key":"1690_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus\u00a0A, Saglio\u00a0G, Hughes\u00a0TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5\u2011year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354.","journal-title":"Leukemia"},{"issue":"3","key":"1690_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.clml.2012.12.005","volume":"13","author":"E Jabbour","year":"2013","unstructured":"Jabbour\u00a0E, Kantarjian\u00a0H, Ghanem\u00a0H, et al. The achievement of a\u00a03-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013;13(3):302\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"1690_CR6","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1002\/cncr.26196","volume":"117","author":"A Quintas-Cardama","year":"2011","unstructured":"Quintas-Cardama\u00a0A, Cortes\u00a0JE, Kantarjian\u00a0HM. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications. Cancer. 2011;117(23):5261\u201370.","journal-title":"Cancer"},{"issue":"9","key":"1690_CR7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","volume":"16","author":"K Merx","year":"2002","unstructured":"Merx\u00a0K, Muller\u00a0MC, Kreil\u00a0S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia. 2002;16(9):1579\u201383.","journal-title":"Leukemia"},{"issue":"6","key":"1690_CR8","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","volume":"120","author":"L Wang","year":"2003","unstructured":"Wang\u00a0L, Pearson\u00a0K, Ferguson\u00a0JE, Clark\u00a0RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003;120(6):990\u20139.","journal-title":"Br J Haematol"},{"issue":"9","key":"1690_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes\u00a0TP, Saglio\u00a0G, Kantarjian\u00a0HM, et\u00a0al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353\u201360.","journal-title":"Blood"},{"issue":"4","key":"1690_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour\u00a0E, Kantarjian\u00a0HM, Saglio\u00a0G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3\u2011year follow-up from a\u00a0randomized phase 3 trial (DASISION). Blood. 2014;123(4):494\u2013500.","journal-title":"Blood"},{"key":"1690_CR11","doi-asserted-by":"crossref","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood. 1984;63(4):789\u201399.","DOI":"10.1182\/blood.V63.4.789.bloodjournal634789"},{"issue":"3","key":"1690_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin\u00a0D, Ibrahim\u00a0AR, Lucas\u00a0C, et al. Assessment of BCR-ABL1 transcript levels at 3\u00a0months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J\u00a0Clin Oncol. 2012;30(3):232\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1690_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm\u00a0E, Altman\u00a0DG, Egger\u00a0M, et\u00a0al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J\u00a0Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1690_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2017","unstructured":"Cortes\u00a0JE, Gambacorti-Passerini\u00a0C, Deininger\u00a0MWN, et al. Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial. J\u00a0Clin Oncol. 2017;36(3):231\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1690_CR15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent\u00a0P, Hadzijusufovic\u00a0E, Schernthaner\u00a0GH, Wolf\u00a0D, Rea\u00a0D, le Coutre\u00a0P. Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood. 2015;125(6):901\u20136.","journal-title":"Blood"},{"issue":"3","key":"1690_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.critrevonc.2011.08.002","volume":"82","author":"P Valent","year":"2012","unstructured":"Valent\u00a0P, Gastl\u00a0G, Geissler\u00a0K, et al. Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions. Crit Rev Oncol Hematol. 2012;82(3):370\u20137.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1690_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","volume":"59","author":"P Valent","year":"2017","unstructured":"Valent\u00a0P, Hadzijusufovic\u00a0E, Hoermann\u00a0G, et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017;59:47\u201354.","journal-title":"Leuk Res"},{"issue":"1","key":"1690_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele\u00a0S, Krauss\u00a0MP, Hehlmann\u00a0R, et\u00a0al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126(1):42\u20139.","journal-title":"Blood"},{"issue":"11","key":"1690_CR19","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann\u00a0R, Lauseker\u00a0M, Saussele\u00a0S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398\u2013406.","journal-title":"Leukemia"},{"issue":"1","key":"1690_CR20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/blood.V130.Suppl_1.897.897","volume":"130","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann\u00a0R, Lauseker\u00a0M, Saussele\u00a0S, et al. Final evaluation of randomized CML-study IV: 10-year survival and evolution of terminal phase. Blood. 2017;130(1):897.","journal-title":"Blood"},{"issue":"12","key":"1690_CR21","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1016\/S2352-3026(16)30167-3","volume":"3","author":"JE Cortes","year":"2016","unstructured":"Cortes\u00a0JE, De Souza\u00a0CA, Ayala\u00a0M, et al. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a\u00a0randomised, open-label trial. Lancet Haematol. 2016;3(12):e581\u2013e91.","journal-title":"Lancet Haematol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-020-01690-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T23:29:21Z","timestamp":1623454161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-020-01690-1"}},"subtitle":["R-EFECT study"],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":21,"journal-issue":{"issue":"15-16","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1690"],"URL":"https:\/\/doi.org\/10.1007\/s00508-020-01690-1","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.L.\u00a0Petzer \u2013 Advisory board member and honoraria recipient of Novartis, BMS, Pfizer, and Incyte. Travel support from BMS and Pfizer. W.R.\u00a0Sperr \u2013 Fee from Novartis and Pfizer. V.\u00a0Buxhofer-Ausch and T.\u00a0Sliwa declare that they have no competing interests. S.\u00a0Schmidt \u2013 Consultant of BMS. Research Grant from Incyte\/Ariad. Advisory board participation and CML registry of Pfizer. R.\u00a0Greil \u2013 Honoraria recipient, consulting or advisor, research funding, travel support, accommodation and expenses from Celgene, Roche, Merck, Takeda, Astra Zeneca, Novartis, Amgen, BMS, MSD, Sandoz, Abbvie, and Janssen. A.\u00a0W\u00f6lfler \u2013 Honoraria recipient of Novartis, BMS, Pfizer, and Incyte. P.\u00a0Pichler declare that she has no competing interests. C.\u00a0Dormann \u2013 Advisory board member of Pfizer and Eli Lilly. Travel support from Novartis, Pfizer, Roche, MDS, Angelini, Ipsen, and Celgene. Speaker honoraria recipient of Roche, Bristol-Myers Squibb, MDS, Pierre Fabre, and AstraZeneca. S.\u00a0Burgstaller \u2013 Advisory board member, travel support, and speaker honoraria recipient of Novartis, AOP Orphan, Celgene, and Takeda. C.\u00a0Tinchon declare that he has no competing interests. A.\u00a0Lang \u2013 Grant from Novartis. F.\u00a0Goebel, S.\u00a0Uthman and N.\u00a0Muenchmeier \u2013 Employees of Novartis. P.\u00a0Valent \u2013 Grant from Celgene and Pfizer. Fee from Novartis, Celgene, Pfizer, Incyte, and Deciphera.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}